

IPAR



**Public Assessment Report for a
Medicinal Product for Human Use**

Scientific Discussion

Prucalopride STADA 2 mg film-coated tablets
Prucalopride
PA0593/045/002

The Public Assessment Report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation for a specific medicinal product for human use. It is made available by the HPRA for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of Directive 2001/83/EC, as amended. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the medicinal product for marketing in Ireland.

CONTENTS

- I. INTRODUCTION
- II. QUALITY ASPECTS
- III. NON-CLINICAL ASPECTS
- IV. CLINICAL ASPECTS
- V. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT
- VI. REVISION DATE
- VII. UPDATE

I. INTRODUCTION

Name of the product	Prucalopride STADA 2 mg film-coated tablets
Name(s) of the active substance(s) (INN)	Prucalopride
Pharmacotherapeutic classification (ATC Code)	A06AX05
Pharmaceutical form and strength(s)	2, mg, Film-coated tablet
Marketing Authorisation Number(s) in Ireland (PA)	PA0593/045/002
Marketing Authorisation Holder	Stada Arzneimittel AG Stadastrasse 2-18 D-61118 Bad Vilbel Germany
MRP/DCP No.	IE/H/0787/002/DC
Reference Member State	Ireland
Concerned Member State(s)	DE DK FI IS SE

Based on the review of the data on quality, safety and efficacy, the HPRA has granted a marketing authorisation for Prucalopride STADA 1 mg film-coated tablets and Prucalopride STADA 2 mg film-coated tablets from Stada Arzneimittel AG on 25th August 2020 for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.

The application was made according to the provisions of Article 10(1) of Directive 2001/83/EC.

This medicinal product is a generic version of the originator product Resolor 1mg and 2mg film-coated tablets film-coated tablets marketed by Shire Pharmaceuticals Ireland Limited, authorised by a centralised procedure EMEA/H/C/001012 and registered since 15th of October 2009.

No scientific advice has been given to the applicant with respect to these products.

The prescription status of the products is "subject to medical prescription"

The Summary of Product Characteristics for (SmPC) for this medicinal product is available on the HPRA's website.

The Summary of Product Characteristics for (SmPC) for this medicinal product is available on the HPRA's website at www.hpra.ie.

II. QUALITY ASPECTS

This application is for Prucalopride STADA 1 mg and 2 mg film-coated tablets.

II.2 Drug substance

The active substance is prucalopride succinate, an established active substance, not described in the European Pharmacopoeia, and is manufactured in accordance with the principles of Good Manufacturing Practice (GMP)

The active substance specification is considered adequate to control the quality and meets current pharmacopoeial requirements. Batch analytical data demonstrating compliance with this specification has been provided.

II.3 Medicinal product**P.1 Composition**

The excipients in the medicinal product are listed in section 6.1 of the SmPC.

A visual description of the product is included in section 3 of the SmPC.

P.2 Pharmaceutical Development

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

P.3 Manufacture of the Product

The product is manufactured in accordance with the principles of good manufacturing practice (GMP) at suitably qualified manufacturing sites.

The manufacturing process has been validated according to relevant European/ICH guidelines and the process is considered to be sufficiently validated.

P.4 Control of Other Substances (Excipients)

All ingredients comply with Ph. Eur. or are adequately controlled by the manufacturer's specifications.

P.5 Control of Finished Product

The Finished Product Specification is based on the pharmacopoeial monograph for tablets, and the tests and control limits are considered appropriate for this type of product.

The analytical methods used are described in sufficient detail and are supported by validation data.

Batch analytical data for a number of batches from the proposed production site have been provided, and demonstrate the ability of the manufacturer to produce batches of finished product of consistent quality.

P.7 Packaging material

The approved packaging for this product is described in section 6.5 of the SmPC.

Evidence has been provided that the packaging complies with Ph. Eur./EU legislation for use with foodstuffs requirements.

P.8 Stability of the Finished Product

Stability data on the finished product in the proposed packaging have been provided in accordance with EU guidelines and support the shelf-life and storage conditions listed in sections 6.3 and 6.4 of the SmPC.

II.4 Discussion on Chemical and Pharmaceutical Aspects

The important quality characteristics of the product are well-defined and controlled. Satisfactory chemical and pharmaceutical documentation has been provided, assuring consistent quality of Prucalopride STADA 1 mg and 2 mg film-coated tablets.

III. NON-CLINICAL ASPECTS

This active substance is a generic formulation of Resolor 1mg and 2mg film-coated tablets film-coated tablets marketed by Shire Pharmaceuticals Ireland Limited, authorised by a centralised procedure EMEA/H/C/001012 on the European market. No new preclinical data have been submitted. As such, no pre-clinical assessment has been made on the application. This is acceptable for this type of application.

IV. CLINICAL ASPECTS

IV.1 Introduction

Prucalopride is a well known active substance with established efficacy and tolerability.

The content of the SmPC approved during the decentralised procedure is in accordance with that accepted for the reference product Resolor 1mg and 2mg film-coated tablets film-coated tablets marketed by Shire Pharmaceuticals Ireland Limited.

For this generic application, no bioequivalence studies have been submitted.

A waiver for all in vivo bioequivalence studies was requested for both strengths. Based on its high solubility and permeability, Prucalopride STADA 1 mg and 2 mg film-coated tablets can be categorized as a BCS Class 1. The drug product is an immediate-release oral dose form with systemic action, and the drug product is a dosage form that is pharmaceutically equivalent to the reference product. As required for a BCS-based biowaver, the drug substance has known human absorption (>90%) and is not considered to have a narrow therapeutic index.

It is agreed there are no differences in excipients or coating in the formulation compared to the reference product that might affect bioavailability.

The applicant's justification for a BCS-based biowaver exemption for in vivo bioequivalence studies meets the criteria detailed in EMA guideline on the investigation of bioequivalence and is accepted. Prucalopride STADA 1 mg and 2 mg film-coated tablets can be considered therapeutic equivalent to the reference formulation.

IV.2 Pharmacokinetics

No new data were provided. This is acceptable for this type of application.

IV.3 Pharmacodynamics

No new data were provided. This is acceptable for this type of application.

IV.4 Clinical Efficacy

No new data were provided. This is acceptable for this type of application.

IV.5 Clinical Safety

No new data were provided. This is acceptable for this type of application.

Risk Management Plan

The applicant has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Prucalopride STADA 1mg and Prucalopride STADA 2mg film coated tablets. The RMP (version 0.3, dated 31/01/20) is acceptable.

Routine risk minimization activities are considered sufficient. The applicant is requested to ensure it maintains the RMP in line with the latest SmPC updates and maintains regular reviews.

With regard to PSUR submission, the MAH should take the following into account:

- PSURs shall be submitted in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. Marketing authorisation holders shall continuously check the European medicines webportal for the DLP and frequency of submission of the next PSUR.

IV.6 Discussion on the clinical aspects

Prucalopride STADA 1 mg and 2 mg film-coated tablets is a generic form of Resolor 1mg and 2mg film-coated tablets. Resolor 1mg and 2mg film-coated tablets is a well-known medicinal product with a proven chemical-pharmaceutical quality and an established favourable efficacy and safety profile.

A waiver for all in vivo bioequivalence studies was requested for both strengths. The applicant's justification for a BCS-based biowaver exemption for in vivo bioequivalence studies meets the criteria detailed in EMA guideline on the investigation of bioequivalence and is accepted. Prucalopride STADA 1 mg and 2 mg film-coated tablets can be considered therapeutic equivalent to the reference formulation.

The SmPC is consistent with that of the reference product.

V. OVERALL CONCLUSIONS

Prucalopride STADA 1 mg and 2 mg film-coated tablets is a generic form of Resolor 1mg and 2mg film-coated tablets.

Resolor 1mg and 2mg film-coated tablets is a well-known medicinal product with a proven chemical-pharmaceutical quality and an established favourable efficacy and safety profile.

Bioequivalence has been shown to be in compliance with the CHMP guidance documents. The SmPC is consistent with that of the reference product.

The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations.

The HPRA, on the basis of the data submitted considered that Prucalopride STADA 1 mg and 2 mg film-coated tablets demonstrated bioequivalence with the reference product as well as a satisfactory risk/benefit profile and therefore granted a marketing authorisation.

VI. REVISION DATE

29.04.2020